Search

A recent study from Bouira, Algeria, focused on chronic inflammatory demyelinating polyneuropathy (CIDP) and its potential link to gut microbiota. The research found that CIDP patients showed a dominance of Firmicutes and Bacteroides phyla in their gut microbiota, with notable levels of Lachnospiraceae bacterium and Bacteroides sp species. The study suggests that short-chain fatty acids produced by Lachnospiraceae may play a role in triggering autoimmune responses leading to CIDP, offering new insights for diagnosis and treatment. For more information, the full article can be accessed through the Romanian Journal of Neurology. [Extracted from the article]

Researchers at Amsterdam University Medical Center have initiated a global prospective observational cohort study, known as INCbase, to investigate chronic inflammatory demyelinating polyneuropathy (CIDP). The primary goal of INCbase is to develop and validate a clinical prediction model for treatment response in CIDP patients. This collaborative effort involves 29 centers across 8 countries and 303 patients to date, aiming to enhance the understanding of CIDP diagnosis and treatment. The study collects data on demographics, clinical history, diagnostics, and clinical outcomes every 6 months for two years, with the option for biomaterial collection. The prediction model will be shared with researchers and clinicians on the INCbase website for further research and implementation. [Extracted from the article]

A recent study conducted at the Faculty of Medicine in Cologne, Germany, explored the gut microbiome in patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) who were treated with intravenous immunoglobulin (IVIg). The study found that CIDP patients had increased bacterial diversity and enrichment of certain bacteria compared to healthy subjects, and IVIg treatment did not significantly alter the gut microbiome in the short term. The researchers suggest that future studies with larger cohorts are needed to confirm these findings and investigate the long-term effects of IVIg treatment on the gut microbiome in CIDP patients. [Extracted from the article]

Researchers at Chongqing Medical University conducted a study to differentiate between Acute Inflammatory Demyelinating Polyneuropathy (AIDP) and acute-onset Chronic Inflammatory Demyelinating Polyneuropathy (A-CIDP) in pediatric patients. The study found that A-CIDP patients were older, required more complex treatments, and had longer time to nadir compared to AIDP patients. Factors such as gastrointestinal dysfunction and numbness were more prevalent in A-CIDP, while AIDP patients had longer hospital stays and more cranial nerve involvement. The study concluded that early detection of A-CIDP may be favored when the condition deteriorates beyond two weeks with lower modified Rankin Scale scores on admission. [Extracted from the article]

A recent study conducted at the University of Minnesota has provided new insights into Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and its diagnostic criteria. The research highlights the lack of a reliable diagnostic biomarker for CIDP and Guillain-Barre Syndrome (GBS), leading to common misdiagnosis and delayed diagnosis. The study emphasizes the importance of utilizing diagnostic criteria to improve accuracy and patient outcomes. However, the low utilization of these criteria in routine clinical care is a challenge that needs to be addressed. Strategies are needed to optimize the adoption of diagnostic criteria to achieve faster and more accurate diagnoses of CIDP and GBS. [Extracted from the article]

Kine Sciences, a biopharmaceutical company, has announced that the first patient has been dosed in its Phase 1b/2a clinical study of KINE-101 for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). KINE-101 is a novel nanopeptide that activates Treg cells to control immune responses. The Phase 1 study of KINE-101, which demonstrated a good safety profile, was completed successfully in October 2023. KINE-101 is also being developed for other indications, including Inflammatory Bowel Disease, Rheumatoid Arthritis, and Non-Alcoholic Steatohepatitis. [Extracted from the article]

A study conducted at Tianjin Medical University General Hospital in China has investigated the proteins associated with Guillain-Barre Syndrome (GBS) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The researchers used high-throughput analysis to identify differentially expressed proteins (DEPs) in the serum of healthy controls, GBS patients, and CIDP patients. The study found that certain proteins were up-regulated or down-regulated in both GBS and CIDP, and the DEPs have the potential to enhance our understanding of the pathogenesis of these neurological disorders. The research has been peer-reviewed and published in the Journal of Neuroimmunology. [Extracted from the article]

A report from the University of Toronto discusses the challenges in diagnosing and treating chronic inflammatory demyelinating polyneuropathy (CIDP) in children. CIDP is a rare autoimmune neurological disorder that affects both pediatric and adult populations. The report highlights the difficulty in differentiating CIDP from inherited neuropathies, such as Charcot-Marie-Tooth disease, and emphasizes the need for genetic testing in patients who do not respond to conventional CIDP therapies. Current treatment options for CIDP include intravenous immunoglobulins, corticosteroids, and plasmapheresis, but the report suggests that novel therapies are needed for patients who do not respond to standard treatments or experience adverse effects. [Extracted from the article]

A patent application by inventor Nizar Souayah describes systems and methods for diagnosing and treating demyelinating neuropathy. The application proposes using electrodes to measure muscle integrity and obtaining a biological sample, such as urine, to determine biomarker activity. By inputting these measures into a regression model, patients with demyelinating neuropathy can be identified and treated with appropriate agents. The patent application provides specific examples for treating distal symmetric polyneuropathy, peripheral neuropathy, and chronic inflammatory demyelinating polyneuropathy. [Extracted from the article]

A recent study conducted at Hebei General Hospital in China has provided new insights into chronic inflammatory demyelinating polyneuropathy (CIDP). CIDP is an acquired immune-mediated neuropathy characterized by clinical progression for more than 2 months. The study focused on acute-onset CIDP (A-CIDP), a subtype of CIDP that presents with rapidly progressive weakness resembling Guillain-Barré syndrome. The researchers reported a case of a 56-year-old female with A-CIDP who tested positive for anti-GM3 and anti-sulfatides antibodies, which are rarely found in A-CIDP. The detection of these antibodies may help distinguish A-CIDP from other variants and guide treatment decisions. The study emphasizes the importance of monitoring relapse and remission symptoms during treatment to prevent secondary damage. [Extracted from the article]

Researchers from the Department of Neurology have published new findings on chronic inflammatory demyelinating polyneuropathy (CIDP), an immune-mediated neuropathy. While CIDP typically affects the peripheral nerves in the limbs, involvement of cranial nerves is rare, and cases of muscle atrophy due to cranial nerve involvement are exceptionally rare. The researchers presented a case of a 30-year-old female patient with CIDP who experienced atrophy of the tongue and sternocleidomastoid muscles, along with tongue muscle fibrillation. The patient also had hypothyroidism caused by Hashimoto's thyroiditis. Treatment with glucocorticoids led to significant improvement in the patient's symptoms, including regeneration of the tongue muscles. This case represents the first documentation of concurrent sternocleidomastoid muscle atrophy in CIDP with hypoglossal nerve involvement. [Extracted from the article]

A recent study conducted at Freie Universitat Berlin explored the potential involvement of the central nervous system (CNS) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The researchers focused on the functional state of melanopsin-expressing retinal ganglion cells (mRGCs) as a potential biomarker for sleep-wake abnormalities and CNS involvement in CIDP. The study found that individuals with CIDP had a significantly reduced melanopsin-mediated post-illumination pupil response (PIPR) compared to healthy controls. This reduction correlated with disease severity, suggesting that PIPR could serve as an easily accessible biomarker for CNS affection in CIDP. [Extracted from the article]

A study conducted at Immanuel Kant Baltic Federal University has reported on chronic inflammatory demyelinating polyneuropathy (CIDP) induced by immune checkpoint inhibitors (ICI). The researchers presented two case reports of patients with skin melanoma who developed demyelinating polyneuropathy after treatment with pembrolizumab or nivolumab. The study emphasizes the importance of recognizing and diagnosing neurological immune-related adverse events (irAE) induced by ICI to prevent delayed treatment and potential complications. The researchers suggest that each case report can provide practical value due to the variability of these events in patients treated with ICI. [Extracted from the article]

Halozyme Therapeutics, Inc. has announced that argenx has received FDA approval for VYVGART Hytrulo, a treatment for chronic inflammatory demyelinating polyneuropathy (CIDP). VYVGART Hytrulo is a once-weekly subcutaneous injection that combines efgartigimod alfa and Halozyme's proprietary recombinant human hyaluronidase enzyme, rHuPH20. This approval marks the first novel mechanism of action for CIDP treatment in 30 years and offers a shorter treatment time for patients. The FDA approval is based on the ADHERE study, which showed significant clinical improvement and a reduction in the risk of relapse. VYVGART Hytrulo is also approved for the treatment of generalized myasthenia gravis. [Extracted from the article]

A recent study conducted at Duke University Medical Center in Durham, North Carolina, explored the immune dysregulation in patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The researchers used multi-parameter flow cytometry to analyze the phenotype and function of peripheral blood mononuclear cells (PBMCs) in CIDP patients. They found that proinflammatory CD4 and CD8 T cells in CIDP patients had an enhanced capacity to produce inflammatory cytokines, and the function of regulatory T cells (Tregs) was impaired. The study suggests that targeting T cells and improving Treg cell function could be potential therapeutic strategies for CIDP. [Extracted from the article]

A recent report from the Bethune International Peace Hospital in China discusses a case of chronic inflammatory demyelinating polyneuropathy (CIDP) combined with pulmonary nocardiosis. CIDP is a rare immune-mediated peripheral neuropathy, while nocardiosis is a destructive opportunistic disease. The patient in this case experienced limb weakness and was initially treated with glucocorticoids, but later developed pulmonary nocardiosis. Despite treatment with antibiotics and intravenous immunoglobulin, the patient's condition worsened and ultimately led to death. The report emphasizes the importance of early detection and treatment of Nocardia infection in CIDP patients receiving immunosuppressive therapy, as well as the need for patient compliance with prophylactic antibiotic use and follow-up appointments. [Extracted from the article]

A recent study conducted by researchers at the University of Turin in Italy explored the use of ultramicronized Palmitoylethanolamide (umPEA) in managing neuropathic pain related to chronic inflammatory demyelinating polyneuropathy (CIDP). CIDP is a rare autoimmune disease characterized by peripheral inflammation and neuropathic pain. The study involved 14 CIDP patients who were already undergoing immunoglobulin therapy. The results showed that the addition of umPEA to immunoglobulins significantly improved neuropathic pain symptoms and quality of life for the patients. The study suggests that umPEA could be a safe and effective treatment option for managing neuropathic pain in CIDP patients, and it highlights the importance of neuroinflammation modulation in the management of CIDP's painful symptoms. [Extracted from the article]

A report from the Ministry of Health of Russia analyzes the neurotoxic effects of amiodarone and statins on the peripheral nervous system, specifically focusing on chronic inflammatory demyelinating polyneuropathy (CIDP). The research emphasizes the importance of early identification of drug-induced neurotoxicity to minimize neurological complications and highlights the need for differential diagnosis with immune-mediated polyneuropathies. The report includes a clinical case of a 72-year-old male patient who developed demyelinating polyneuropathy after receiving amiodarone and statins, with significant improvement upon discontinuation of amiodarone. The study provides valuable insights into the frequency and manifestations of CIDP caused by these medications. [Extracted from the article]

A recent study conducted at King Saud University in Riyadh, Saudi Arabia, has reported new findings on chronic inflammatory demyelinating polyneuropathy (CIDP). The study focused on a rare metabolic syndrome called Brown-Vialetto-Van Laere (BVVL) syndrome, which is caused by a defect in the riboflavin transporter genes. BVVL syndrome is characterized by progressive auditory neuropathy, muscle weakness, and respiratory compromise. The study found that early administration of riboflavin can improve or halt disease progression, leading to reduced mortality and morbidity. This research highlights the importance of considering BVVL syndrome in patients with specific clinical symptoms. [Extracted from the article]

A recent study conducted by researchers at Hamamatsu University School of Medicine in Japan has found a link between chronic inflammatory demyelinating polyneuropathy (CIDP) and membranous nephropathy (MN). The study focused on a 50-year-old man with CIDP who was found to have MN upon kidney biopsy. The researchers discovered the presence of anti-contactin 1 (CNTN1) antibodies in the patient's serum, indicating an association between CIDP and MN. The study suggests that a variety of autoantibodies may be produced in CIDP cases associated with CNTN1 antibodies and MN. [Extracted from the article]

A Phase 3 clinical trial is being conducted to evaluate the effectiveness and safety of a drug called Riliprubart compared to a placebo in adult participants with refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The study will last for a maximum of 109 weeks and will include screening, treatment phases, and follow-up. Participants must meet specific criteria, including a confirmed diagnosis of CIDP and refractoriness to immunoglobulin or corticosteroid therapy. The study is not yet recruiting and is estimated to be completed by October 12, 2027. The document outlines the eligibility criteria for participants, including contraceptive requirements and exclusion criteria for certain medical conditions or histories. The responsible party for the study is Sanofi, and data sharing is planned. [Extracted from the article]

The document provides information about a clinical trial, NCT06290141, which aims to compare the effectiveness and safety of riliprubart and intravenous immunoglobulin (IVIg) in adult patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) who are currently receiving IVIg treatment. The study will last for a maximum of 109 weeks and will include screening, treatment phases, and follow-up. The recruitment for the study has not yet started, and the estimated completion date is May 19, 2027. The document also outlines the eligibility criteria for participants, including specific medical conditions, vaccinations, and contraception requirements. The study is being conducted by Sanofi, and the data may be shared with qualified researchers. [Extracted from the article]

A recent study conducted by researchers at the College of Medicine in Kathmandu, Nepal, focused on chronic inflammatory demyelinating polyneuropathy (CIDP), a rare but treatable immune-mediated chronic disorder of the peripheral nervous system. The study described the case of a 13-year-old indigenous girl who presented with progressive muscle weakness in her limbs and bilateral sensory neural hearing loss. After receiving a diagnosis of CIDP, the patient was treated with IV Methylprednisolone and Azathioprine, which improved her symptoms. The researchers emphasized the importance of timely intervention and early diagnosis in pediatric cases of CIDP to improve prognosis. [Extracted from the article]

This document describes a patent application for methods of treating chronic inflammatory demyelinating polyneuropathy (CIDP) and cold-agglutinin disease using a humanized antibody that specifically binds complement component C1s. The methods involve administering loading doses and maintenance doses of the antibody at specific intervals. The patent application provides detailed information about the amino acid sequences of the antibody and the dosing regimens. For more information, readers can refer to the full patent application. [Extracted from the article]

A recent study from the University of Cape Town discusses a case of acute inflammatory demyelinating polyneuropathy (AIDP) as a complication of leptospirosis, a zoonotic disease that primarily affects the liver and kidneys. The study presents the case of a young adult with leptospirosis who developed AIDP, which is a rare neurological manifestation of the disease. This is the first reported case of AIDP as a complication of leptospirosis in South Africa. The study provides valuable insights into the relationship between leptospirosis and neurological complications. [Extracted from the article]

A recent report from Indiana University School of Medicine discusses a case study of a boy with X-linked adrenoleukodystrophy (X-ALD) who exhibited lumbar nerve root enhancement on a screening MRI of the spine. The boy was later diagnosed with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) based on electromyography, nerve conduction studies, and serial imaging. This case highlights the association between X-ALD and CIDP and provides insight into the possible mechanisms underlying this connection. The report also reviews the differential diagnosis of cauda equina nerve root enhancement. [Extracted from the article]

A new study published in the journal Pain & Central Nervous System Week explores the impact of chronic inflammatory demyelinating polyneuropathy (CIDP) on the visual system through visual evoked potentials (VEPs). The study found that CIDP patients consistently exhibited prolonged latencies and reduced amplitudes in VEPs compared to healthy controls, suggesting that the demyelinating process extends to the central nervous system. The review highlights the potential diagnostic and prognostic value of VEP assessment in CIDP management, as well as the challenges associated with recording techniques and the need for standardized protocols. Further research in this area may lead to improved diagnostic accuracy and monitoring strategies for CIDP patients. [Extracted from the article]

The Chronic Inflammatory Demyelinating Polyneuropathy Market Insights report by DelveInsight provides an overview of the current treatment practices and emerging drugs for chronic inflammatory demyelinating polyneuropathy (CIDP). The report includes market share information for individual therapies and forecasts the market size from 2019 to 2032 in the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The analysis shows that the CIDP therapeutics market is projected to increase during the forecast period. Leading pharmaceutical companies such as Octapharma, argenx, Immunovant Sciences, Sanofi, Janssen, and Takeda are developing novel CIDP drugs. The report also provides an overview of CIDP, its symptoms, and diagnostic methods. [Extracted from the article]

A recent report from Western Sydney University discusses the use of baricitinib, a Janus kinase (JAK) inhibitor, in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) caused by immune checkpoint inhibitor (ICI) use. ICIs have revolutionized cancer management but can lead to immune-related adverse events (irAEs). Traditionally, corticosteroids have been used to manage irAEs, but a more tailored approach is needed for refractory cases. The study suggests that modulation of the JAK pathway may be a promising avenue for targeted management of irAEs. Further research is needed in this area. [Extracted from the article]

A recent study conducted at the Hospital Universitario de San Ignacio has reported on two cases of atypical acute inflammatory demyelinating polyneuropathy (AIDP) in individuals with HIV infection. AIDP is an immune-mediated disorder that affects the peripheral nerves, resulting in myelin damage and sometimes axonal loss. The patients in the study experienced neurological symptoms such as progressive weakness and attenuation of tendinous reflexes. Both patients recovered after receiving intravenous immunoglobulin and temporary cessation of antiretroviral therapy. This research provides valuable insights into the relationship between HIV infection and AIDP. [Extracted from the article]

A recent study conducted by researchers at the University of Turin in Italy has explored the use of subcutaneous immunoglobulin (SCIg) as a treatment for chronic inflammatory demyelinating polyneuropathy (CIDP). The study found that SCIg is as effective as intravenous immunoglobulin (IVIg) but offers several advantages, including better tolerance, easier administration, and improved quality of life for patients. The availability of highly concentrated subcutaneous solutions and new technological devices has further enhanced the delivery of SCIg. The study concludes that SCIg has become a well-established therapy for CIDP and provides a historical perspective on its evolution. [Extracted from the article]

Keywords: Chronic Inflammatory Demyelinating Polyneuropathy; Cytokines; Demyelinating Polyneuropathy; Genetics; Health and Medicine; Immunology; Intercellular Signaling Peptides and Proteins; Nervous System Diseases and Conditions; Neurology; Neuromuscular Diseases and Conditions; Peripheral Nervous System Diseases and Conditions; Polyneuropathies EN Chronic Inflammatory Demyelinating Polyneuropathy Cytokines Demyelinating Polyneuropathy Genetics Health and Medicine Immunology Intercellular Signaling Peptides and Proteins Nervous System Diseases and Conditions Neurology Neuromuscular Diseases and Conditions Peripheral Nervous System Diseases and Conditions Polyneuropathies 487 487 1 09/11/23 20230912 NES 230912 2023 SEP 14 (NewsRx) -- By a News Reporter-Staff News Editor at Hematology Week -- Investigators publish new report on chronic inflammatory demyelinating polyneuropathy. Chronic Inflammatory Demyelinating Polyneuropathy, Cytokines, Demyelinating Polyneuropathy, Genetics, Health and Medicine, Immunology, Intercellular Signaling Peptides and Proteins, Nervous System Diseases and Conditions, Neurology, Neuromuscular Diseases and Conditions, Peripheral Nervous System Diseases and Conditions, Polyneuropathies. [Extracted from the article]

Chronic Inflammatory Demyelinating Polyneuropathy, Cytokines, Demyelinating Polyneuropathy, Genetics, Health and Medicine, Intercellular Signaling Peptides and Proteins, Nervous System Diseases and Conditions, Neurology, Neuromuscular Diseases and Conditions, Non-Insulin Dependent Diabetes Mellitus, Nutritional and Metabolic Diseases and Conditions, Peripheral Nervous System Diseases and Conditions, Polyneuropathies, Type 2 Diabetes Keywords: Chronic Inflammatory Demyelinating Polyneuropathy; Cytokines; Demyelinating Polyneuropathy; Genetics; Health and Medicine; Intercellular Signaling Peptides and Proteins; Nervous System Diseases and Conditions; Neurology; Neuromuscular Diseases and Conditions; Non-Insulin Dependent Diabetes Mellitus; Nutritional and Metabolic Diseases and Conditions; Peripheral Nervous System Diseases and Conditions; Polyneuropathies; Type 2 Diabetes EN Chronic Inflammatory Demyelinating Polyneuropathy Cytokines Demyelinating Polyneuropathy Genetics Health and Medicine Intercellular Signaling Peptides and Proteins Nervous System Diseases and Conditions Neurology Neuromuscular Diseases and Conditions Non-Insulin Dependent Diabetes Mellitus Nutritional and Metabolic Diseases and Conditions Peripheral Nervous System Diseases and Conditions Polyneuropathies Type 2 Diabetes 410 410 1 09/11/23 20230911 NES 230911 2023 SEP 11 (NewsRx) -- By a News Reporter-Staff News Editor at Diabetes Week -- Investigators publish new report on chronic inflammatory demyelinating polyneuropathy. [Extracted from the article]

Keywords: Charlotte; State:North Carolina; United States; North and Central America; Chronic Inflammatory Demyelinating Polyneuropathy; Demyelinating Polyneuropathy; Health and Medicine; Nervous System Diseases and Conditions; Neurology; Neuromuscular Diseases and Conditions; Peripheral Nervous System Diseases and Conditions; Polyneuropathies EN Charlotte State:North Carolina United States North and Central America Chronic Inflammatory Demyelinating Polyneuropathy Demyelinating Polyneuropathy Health and Medicine Nervous System Diseases and Conditions Neurology Neuromuscular Diseases and Conditions Peripheral Nervous System Diseases and Conditions Polyneuropathies 6679 6679 1 08/14/23 20230818 NES 230818 2023 AUG 18 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Research findings on Nervous System Diseases and Conditions - Chronic Inflammatory Demyelinating Polyneuropathy are discussed in a new report. Charlotte, State:North Carolina, United States, North and Central America, Chronic Inflammatory Demyelinating Polyneuropathy, Demyelinating Polyneuropathy, Health and Medicine, Nervous System Diseases and Conditions, Neurology, Neuromuscular Diseases and Conditions, Peripheral Nervous System Diseases and Conditions, Polyneuropathies. [Extracted from the article]

Antineoplastics, Chronic Inflammatory Demyelinating Polyneuropathy, Demyelinating Polyneuropathy, Health and Medicine, Immunoglobulins, Immunology, Immunoproteins, Nervous System Diseases and Conditions, Neurology, Neuromuscular Diseases and Conditions, Peripheral Nervous System Diseases and Conditions, Polyneuropathies, Proteins, Serum Globulins Keywords for this news article include: Aarhus University Hospital, Aarhus, Denmark, Europe, Antineoplastics, Neurology, Immunology, Immunoproteins, Immunoglobulins, Serum Globulins, Polyneuropathies, Health and Medicine, Neuromuscular Diseases and Conditions, Chronic Inflammatory Demyelinating Polyneuropathy, Peripheral Nervous System Diseases and Conditions. Keywords: Antineoplastics; Chronic Inflammatory Demyelinating Polyneuropathy; Demyelinating Polyneuropathy; Health and Medicine; Immunoglobulins; Immunology; Immunoproteins; Nervous System Diseases and Conditions; Neurology; Neuromuscular Diseases and Conditions; Peripheral Nervous System Diseases and Conditions; Polyneuropathies; Proteins; Serum Globulins EN Antineoplastics Chronic Inflammatory Demyelinating Polyneuropathy Demyelinating Polyneuropathy Health and Medicine Immunoglobulins Immunology Immunoproteins Nervous System Diseases and Conditions Neurology Neuromuscular Diseases and Conditions Peripheral Nervous System Diseases and Conditions Polyneuropathies Proteins Serum Globulins 5610 5610 1 07/17/23 20230721 NES 230721 2023 JUL 21 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Investigators discuss new findings in chronic inflammatory demyelinating polyneuropathy. [Extracted from the article]

Furthermore, we performed cell clustering, cell annotation, cell-cell communication, differentially expressed genes (DEGs) identification and pseudotime trajectory analysis. Keywords: Heilongjiang; People's Republic of China; Asia; Acute Inflammatory Demyelinating Polyneuropathy; Autoimmune Diseases and Conditions; Blood Cells; Bone Marrow Cells; Cell Research; Demyelinating Polyneuropathy; Health and Medicine; Hemic and Immune Systems; Immunology; Monocytes; Mononuclear Leukocytes; Mononuclear Phagocyte System; Myeloid Cells; Nervous System Diseases and Conditions; Neurology; Neuromuscular Diseases and Conditions; Peripheral Nervous System Diseases and Conditions; Phagocytes; Polyneuropathies EN Heilongjiang People's Republic of China Asia Acute Inflammatory Demyelinating Polyneuropathy Autoimmune Diseases and Conditions Blood Cells Bone Marrow Cells Cell Research Demyelinating Polyneuropathy Health and Medicine Hemic and Immune Systems Immunology Monocytes Mononuclear Leukocytes Mononuclear Phagocyte System Myeloid Cells Nervous System Diseases and Conditions Neurology Neuromuscular Diseases and Conditions Peripheral Nervous System Diseases and Conditions Phagocytes Polyneuropathies 1704 1704 1 07/17/23 20230721 NES 230721 2023 JUL 21 (NewsRx) -- By a News Reporter-Staff News Editor at Genomics & Genetics Weekly -- Fresh data on Autoimmune Diseases and Conditions - Acute Inflammatory Demyelinating Polyneuropathy are presented in a new report. [Extracted from the article]

Winston-Salem, State:North Carolina, United States, North and Central America, Demyelinating Polyneuropathy, Health and Medicine, Nervous System Diseases and Conditions, Neurology, Neuromuscular Diseases and Conditions, Peripheral Nervous System Diseases and Conditions, Polyneuropathies, Chronic Inflammatory Demyelinating Polyneuropathy Keywords: Winston-Salem; State:North Carolina; United States; North and Central America; Chronic Inflammatory Demyelinating Polyneuropathy; Demyelinating Polyneuropathy; Health and Medicine; Nervous System Diseases and Conditions; Neurology; Neuromuscular Diseases and Conditions; Peripheral Nervous System Diseases and Conditions; Polyneuropathies EN Winston-Salem State:North Carolina United States North and Central America Chronic Inflammatory Demyelinating Polyneuropathy Demyelinating Polyneuropathy Health and Medicine Nervous System Diseases and Conditions Neurology Neuromuscular Diseases and Conditions Peripheral Nervous System Diseases and Conditions Polyneuropathies 4874 4874 1 06/19/23 20230624 NES 230624 2023 JUN 23 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Imaging Week -- Data detailed on Nervous System Diseases and Conditions - Chronic Inflammatory Demyelinating Polyneuropathy have been presented. [Extracted from the article]

Okazaki, Japan, Asia, Demyelinating Polyneuropathy, Health and Medicine, Nervous System Diseases and Conditions, Neurology, Neuromuscular Diseases and Conditions, Peripheral Nervous System Diseases and Conditions, Polyneuropathies, Chronic Inflammatory Demyelinating Polyneuropathy Keywords: Okazaki; Japan; Asia; Chronic Inflammatory Demyelinating Polyneuropathy; Demyelinating Polyneuropathy; Health and Medicine; Nervous System Diseases and Conditions; Neurology; Neuromuscular Diseases and Conditions; Peripheral Nervous System Diseases and Conditions; Polyneuropathies EN Okazaki Japan Asia Chronic Inflammatory Demyelinating Polyneuropathy Demyelinating Polyneuropathy Health and Medicine Nervous System Diseases and Conditions Neurology Neuromuscular Diseases and Conditions Peripheral Nervous System Diseases and Conditions Polyneuropathies 217 217 1 06/12/23 20230617 NES 230617 2023 JUN 17 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Imaging Week -- Researchers detail new data in Nervous System Diseases and Conditions - Chronic Inflammatory Demyelinating Polyneuropathy. [Extracted from the article]

Keywords: Antibodies; Antineoplastics; Blood Proteins; Chronic Inflammatory Demyelinating Polyneuropathy; Chronic Inflammatory Demyelinating Polyradiculoneuropathy; Demyelinating Polyneuropathy; Health and Medicine; Immunoglobulin G; Immunoglobulins; Immunology; Immunoproteins; Intravenous Immunoglobulin; Intravenous Immunoglobulins; Nervous System Diseases and Conditions; Neurology; Neuromuscular Diseases and Conditions; Peripheral Nervous System Diseases and Conditions; Polyneuropathies; Proteins; Serum Globulins EN Antibodies Antineoplastics Blood Proteins Chronic Inflammatory Demyelinating Polyneuropathy Chronic Inflammatory Demyelinating Polyradiculoneuropathy Demyelinating Polyneuropathy Health and Medicine Immunoglobulin G Immunoglobulins Immunology Immunoproteins Intravenous Immunoglobulin Intravenous Immunoglobulins Nervous System Diseases and Conditions Neurology Neuromuscular Diseases and Conditions Peripheral Nervous System Diseases and Conditions Polyneuropathies Proteins Serum Globulins 7391 7391 1 06/12/23 20230616 NES 230616 2023 JUN 16 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- New study results on chronic inflammatory demyelinating polyneuropathy have been published. Antibodies, Antineoplastics, Blood Proteins, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Demyelinating Polyneuropathy, Health and Medicine, Immunoglobulin G, Immunoglobulins, Immunology, Immunoproteins, Intravenous Immunoglobulin, Nervous System Diseases and Conditions, Neurology, Neuromuscular Diseases and Conditions, Peripheral Nervous System Diseases and Conditions, Polyneuropathies, Proteins, Serum Globulins, Intravenous Immunoglobulins. [Extracted from the article]

Izmir, Turkey, Eurasia, Chronic Inflammatory Demyelinating Polyneuropathy, Demyelinating Polyneuropathy, Health and Medicine, Nervous System Diseases and Conditions, Neurology, Neuromuscular Diseases and Conditions, Pediatrics, Peripheral Nervous System Diseases and Conditions, Plasmapheresis, Polyneuropathies, Sorption Detoxification Keywords: Izmir; Turkey; Eurasia; Chronic Inflammatory Demyelinating Polyneuropathy; Demyelinating Polyneuropathy; Health and Medicine; Nervous System Diseases and Conditions; Neurology; Neuromuscular Diseases and Conditions; Pediatrics; Peripheral Nervous System Diseases and Conditions; Plasmapheresis; Polyneuropathies; Sorption Detoxification EN Izmir Turkey Eurasia Chronic Inflammatory Demyelinating Polyneuropathy Demyelinating Polyneuropathy Health and Medicine Nervous System Diseases and Conditions Neurology Neuromuscular Diseases and Conditions Pediatrics Peripheral Nervous System Diseases and Conditions Plasmapheresis Polyneuropathies Sorption Detoxification 140 140 1 06/12/23 20230616 NES 230616 2023 JUN 17 (NewsRx) -- By a News Reporter-Staff News Editor at Pediatrics Week -- New research on Nervous System Diseases and Conditions - Chronic Inflammatory Demyelinating Polyneuropathy is the subject of a report. [Extracted from the article]

Intravenous immunoglobulin (1.0 g/kg) was efficacious and well tolerated as maintenance treatment for patients with chronic inflammatory demyelinating polyneuropathy. Keywords: Antibodies; Antineoplastics; Blood Proteins; Chronic Inflammatory Demyelinating Polyneuropathy; Clinical Research; Clinical Trials and Studies; Demyelinating Polyneuropathy; Health and Medicine; Immunoglobulin G; Immunoglobulins; Immunology; Immunoproteins; Intravenous Immunoglobulin; Intravenous Immunoglobulins; Nervous System Diseases and Conditions; Neurology; Neuromuscular Diseases and Conditions; Peripheral Nervous System Diseases and Conditions; Polyneuropathies; Proteins; Serum Globulins; Therapy EN Antibodies Antineoplastics Blood Proteins Chronic Inflammatory Demyelinating Polyneuropathy Clinical Research Clinical Trials and Studies Demyelinating Polyneuropathy Health and Medicine Immunoglobulin G Immunoglobulins Immunology Immunoproteins Intravenous Immunoglobulin Intravenous Immunoglobulins Nervous System Diseases and Conditions Neurology Neuromuscular Diseases and Conditions Peripheral Nervous System Diseases and Conditions Polyneuropathies Proteins Serum Globulins Therapy 519 519 1 05/22/23 20230523 NES 230523 2023 MAY 22 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- New research on chronic inflammatory demyelinating polyneuropathy is the subject of a new report. [Extracted from the article]

Results: A total of 34 CIDP, 15 AIDP and 16 axonal neuropathies (including eight axonal Guillain-Barre syndrome (GBS), four hereditary transthyretin amyloidosis, three diabetic polyneuropathy and one vasculitic neuropathy) were included. Keywords: Chronic Inflammatory Demyelinating Polyneuropathy; Demyelinating Polyneuropathy; Health and Medicine; Nervous System Diseases and Conditions; Neurology; Neuromuscular Diseases and Conditions; Neuropathy; Peripheral Nervous System Diseases and Conditions; Polyneuropathies EN Chronic Inflammatory Demyelinating Polyneuropathy Demyelinating Polyneuropathy Health and Medicine Nervous System Diseases and Conditions Neurology Neuromuscular Diseases and Conditions Neuropathy Peripheral Nervous System Diseases and Conditions Polyneuropathies 298 298 1 05/15/23 20230519 NES 230519 2023 MAY 20 (NewsRx) -- By a News Reporter-Staff News Editor at Pain & Central Nervous System Week -- A new study on chronic inflammatory demyelinating polyneuropathy is now available. [Extracted from the article]

Furthermore, we performed cell clustering, cell annotation, cell-cell communication, differentially expressed genes (DEGs) identification and pseudotime trajectory analysis. According to the news reporters, the research concluded: "Furthermore, we observed increased IL1b-IL1R2 cell-cell communication between CD14+ and CD16+ monocytes. Keywords: Acute Inflammatory Demyelinating Polyneuropathy; Autoimmune Diseases and Conditions; Blood Cells; Bone Marrow Cells; Cell Research; Demyelinating Polyneuropathy; Health and Medicine; Hemic and Immune Systems; Immunology; Monocytes; Mononuclear Leukocytes; Mononuclear Phagocyte System; Myeloid Cells; Nervous System Diseases and Conditions; Neurology; Neuromuscular Diseases and Conditions; Peripheral Nervous System Diseases and Conditions; Phagocytes; Polyneuropathies EN Acute Inflammatory Demyelinating Polyneuropathy Autoimmune Diseases and Conditions Blood Cells Bone Marrow Cells Cell Research Demyelinating Polyneuropathy Health and Medicine Hemic and Immune Systems Immunology Monocytes Mononuclear Leukocytes Mononuclear Phagocyte System Myeloid Cells Nervous System Diseases and Conditions Neurology Neuromuscular Diseases and Conditions Peripheral Nervous System Diseases and Conditions Phagocytes Polyneuropathies 1437 1437 1 05/02/23 20230505 NES 230505 2023 MAY 5 (NewsRx) -- By a News Reporter-Staff News Editor at Genomics & Genetics Weekly -- Data detailed on acute inflammatory demyelinating polyneuropathy have been presented. [Extracted from the article]

Philadelphia, State:Pennsylvania, United States, North and Central America, Chronic Inflammatory Demyelinating Polyneuropathy, Cranial Nerve Diseases and Conditions, Demyelinating Polyneuropathy, Eye Diseases and Conditions, Health and Medicine, Nervous System Diseases and Conditions, Neurology, Neuromuscular Diseases and Conditions, Neuropathy, Optic Nerve Diseases and Conditions, Papilledema, Peripheral Nervous System Diseases and Conditions, Polyneuropathies Keywords: Philadelphia; State:Pennsylvania; United States; North and Central America; Chronic Inflammatory Demyelinating Polyneuropathy; Cranial Nerve Diseases and Conditions; Demyelinating Polyneuropathy; Eye Diseases and Conditions; Health and Medicine; Nervous System Diseases and Conditions; Neurology; Neuromuscular Diseases and Conditions; Neuropathy; Optic Nerve Diseases and Conditions; Papilledema; Peripheral Nervous System Diseases and Conditions; Polyneuropathies EN Philadelphia State:Pennsylvania United States North and Central America Chronic Inflammatory Demyelinating Polyneuropathy Cranial Nerve Diseases and Conditions Demyelinating Polyneuropathy Eye Diseases and Conditions Health and Medicine Nervous System Diseases and Conditions Neurology Neuromuscular Diseases and Conditions Neuropathy Optic Nerve Diseases and Conditions Papilledema Peripheral Nervous System Diseases and Conditions Polyneuropathies 561 561 1 04/17/23 20230421 NES 230421 2023 APR 17 (NewsRx) -- By a News Reporter-Staff News Editor at Pain & Central Nervous System Week -- Data detailed on Nervous System Diseases and Conditions - Chronic Inflammatory Demyelinating Polyneuropathy have been presented. [Extracted from the article]